Sang-Moo Kang Selected Research

Virus-Like Particle Vaccines

1/2017	Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
11/2015	Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
10/2014	Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
12/2011	Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.
5/2011	H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals.
1/2010	Influenza immunization with trehalose-stabilized virus-like particle vaccine using microneedles.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sang-Moo Kang Research Topics

Disease

80	Human Influenza (Influenza) 07/2022 - 09/2003
35	Infections 06/2022 - 01/2007
19	Respiratory Syncytial Virus Infections 04/2022 - 10/2011
19	Weight Loss (Weight Reduction) 10/2021 - 01/2011
10	Influenza in Birds (Avian Flu) 01/2020 - 04/2007
7	Pneumonia (Pneumonitis) 01/2022 - 01/2007
6	Virus Diseases (Viral Diseases) 09/2022 - 01/2007
5	Inflammation (Inflammations) 01/2020 - 01/2013
5	Eosinophilia 11/2017 - 01/2015
5	Lung Diseases (Lung Disease) 11/2015 - 10/2014
3	COVID-19 06/2022 - 01/2021
3	Body Weight (Weight, Body) 01/2022 - 11/2010
3	Communicable Diseases (Infectious Diseases) 08/2021 - 01/2009
3	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 01/2019 - 04/2014
2	Neoplasms (Cancer) 05/2021 - 06/2015
2	Respiratory Hypersensitivity 01/2017 - 01/2016
1	Respiratory Tract Diseases (Respiratory Tract Disease) 04/2021
1	Wasting Syndrome (Wasting Disease) 01/2020
1	Colitis 01/2020
1	Lung Injury 01/2019
1	Body Weight Changes 01/2019
1	Toxoplasmosis 11/2018
1	Airway Obstruction (Choking) 01/2017
1	Coinfection 03/2016
1	Breast Neoplasms (Breast Cancer) 06/2015

Drug/Important Bio-Agent (IBA)

66	VaccinesIBA 07/2022 - 09/2003
23	Proteins (Proteins, Gene)FDA Link 09/2022 - 01/2009
21	CytokinesIBA 01/2022 - 08/2006
20	Hemagglutinins (Hemagglutinin)IBA 11/2021 - 10/2007
17	AntibodiesIBA 10/2021 - 04/2007
16	AntigensIBA 07/2022 - 06/2008
14	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2020 - 06/2008
11	Immunoglobulin G (IgG)IBA 01/2022 - 01/2005
9	Formaldehyde (Formol)FDA Link 06/2019 - 01/2005
9	InterferonsIBA 01/2019 - 10/2012
6	EpitopesIBA 09/2022 - 11/2018
6	Antiviral Agents (Antivirals)IBA 03/2021 - 10/2012
6	Neuraminidase (Sialidase)IBA 01/2021 - 01/2009
6	Virus-Like Particle VaccinesIBA 01/2017 - 01/2010
6	TrehaloseIBA 10/2012 - 01/2010
5	Interleukin-6 (Interleukin 6)IBA 11/2016 - 01/2007
4	DNA (Deoxyribonucleic Acid)IBA 06/2019 - 07/2012
4	Respiratory Syncytial Virus VaccinesIBA 01/2019 - 02/2015
3	Immune Sera (Antisera)IBA 09/2022 - 04/2007
3	ChemokinesIBA 01/2022 - 01/2015
3	FlagellinIBA 01/2021 - 11/2010
3	Amino Acids FDA Link 01/2019 - 09/2013
3	InterleukinsIBA 01/2017 - 01/2015
3	Interleukin-4 (Interleukin 4)IBA 01/2016 - 01/2007
3	DNA VaccinesIBA 10/2014 - 06/2012
3	Glycoproteins (Glycoprotein)IBA 10/2014 - 10/2007
2	Drinking WaterIBA 01/2022 - 01/2019
2	CadmiumIBA 01/2022 - 01/2019
2	Cell Wall SkeletonIBA 01/2022 - 05/2021
2	monophosphoryl lipid AIBA 01/2022 - 10/2017
2	COVID-19 VaccinesIBA 08/2021 - 01/2021
2	Vaccine AdjuvantsIBA 05/2021 - 10/2020
2	Fc Receptors (Fc Receptor)IBA 03/2021 - 10/2014
2	Monoclonal AntibodiesIBA 01/2020 - 09/2013
2	Glycerophospholipids (Phosphoglycerides)IBA 01/2019 - 11/2016
2	Complement System Proteins (Complement)IBA 01/2019 - 10/2018
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018 - 01/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 11/2016
2	Inactivated VaccinesIBA 04/2016 - 08/2014
2	Peptides (Polypeptides)IBA 01/2016 - 01/2015
2	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 07/2015 - 06/2015
2	aluminum sulfate (alum)IBA 01/2015 - 12/2013
2	Viral AntigensIBA 08/2011 - 08/2006
2	Oleic Acid (Oleate)IBA 01/2009 - 08/2006
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2009 - 08/2006
2	Immunoglobulin A (IgA)IBA 01/2007 - 01/2005
1	Combined VaccinesIBA 06/2022
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2022
1	SaponinsIBA 01/2022
1	saponin QA-21V1 (QS21)IBA 01/2022
1	EmulsionsIBA 10/2021
1	AddavaxIBA 10/2021
1	mRNA VaccinesIBA 08/2021
1	AerosolsIBA 04/2021
1	Ethanol (Ethyl Alcohol)IBA 01/2021
1	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2020
1	Carnitine (L-Carnitine)FDA LinkGeneric 01/2019
1	Branched-Chain Amino AcidsIBA 01/2019
1	ProteomeIBA 01/2019
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2019
1	Surface Antigens (Surface Antigen)IBA 11/2018
1	LigandsIBA 01/2018
1	OligodeoxyribonucleotidesIBA 10/2017
1	GTP-Binding Proteins (G-Protein)IBA 01/2017
1	Interleukin-10 (Interleukin 10)IBA 11/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 11/2016
1	Cysteine (L-Cysteine)FDA Link 11/2016
1	PurinesIBA 11/2016
1	PyrimidinesIBA 11/2016
1	Tryptophan (L-Tryptophan)FDA Link 11/2016
1	Neutralizing AntibodiesIBA 04/2016
1	NucleoproteinsIBA 03/2016
1	Subunit VaccinesIBA 06/2015

Therapy/Procedure

4	Oral Administration 07/2014 - 10/2012
2	Intramuscular Injections 11/2010 - 03/2010